This invention pertains to the discovery administration of a CCK receptor agonist can increase urinary sodium excretion and/or free water excretion in a mammal. CCK receptor agonist can thereby be used in the treatment of conditions such high blood pressure fluid retention associated with heart failure fluid retention associated with acute or chronic kidney failure fluid retention associated with cirrhosis fluid retention associated with liver failure calcium kidney stones nephrogenic diabetes i...

The present invention is directed to the use of the peptide compound Tyr-Val-Met-Gly-His-Phe-Arg-Trp-Asp-Arg-Phe-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer autoimmune diseases fibrotic diseases inflammatory diseases neurodegenerative diseases infectious diseases lung diseases heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or arti...

The present invention is directed to the use of the peptide compound Tyr-Val-Met-Gly-His-Phe-Arg-Trp-Asp-Arg-Phe-NHas a therapeutic agent for the prophylaxis and/or treatment of cancer autoimmune diseases fibrotic diseases inflammatory diseases neurodegenerative diseases infectious diseases lung diseases heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquide buffer solution or artif...

The present invention is directed to the use of the peptide compound Tyr-Val-Met-Gly- His-Phe-Arg-Trp-Asp-Arg-Phe-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer autoimmune diseases fibrotic diseases inflammatory diseases neurodegenerative diseases infectious diseases lung diseases heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquide buffer solution or ar...

The present invention is directed to the use of the peptide compound Boc-β-Ala-Trp- Met-Asp-Phe-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer autoimmune diseases fibrotic diseases inflammatory diseases neurodegenerative diseases infectious diseases lung diseases heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother mil...

This invention pertains to the discovery that pentagastrin when administered in conjunction with a proton pump inhibitor (PPI) is synergistic with the PPI and significantly increases the efficacy of the PPI in reducing/mitigating excess gastric acid secretion.